Publication update – National SACT Breast regimen specific consent forms

New consent forms for breast cancer have been added to the CRUK website at www.cruk.org/sact_consent. Some existing forms have been updated as well.

The new regimens include:

  1. Alpelisib
  2. Olaparib
  3. Pembrolizumab – Carboplatin – Paclitaxel – EC
  4. Pembrolizumab and Paclitaxel
  5. Pembrolizumab and Paclitaxel Albumin-Bound
  6. Sacituzumab Govitecan

Regimens that have been updated include:

  1. Capecitabine
  2. Neratinib
  3. Palbociclib
  4. Ribociclib
  5. Trastuzumab
  6. Vinorelbine
  7. Vinorelbine and Capecitabine

Please share this update within your clinical teams or forward to the relevant lead cancer clinician for your organisation.

Any questions, please do let me know.

Best wishes,

Alia

Alia Nizam |Specialist Oncology Pharmacist. CRUK – Information Lead|

Guy’s and St Thomas’ NHS Foundation Trust

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article